Fruquintinib in Combination With Sintilimab in Patients With Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This study is composed of dose escalation stage and dose expansion stage. In dose escalation
stage, patients with advanced solid tumor will be enrolled and administrated with
Fruquintinib in combination with Sintilimab. The MTD ( maximum tolerated dose) or RP2D (
Recommended Phase 2 Dose) will be determined in this stage. In dose expansion stage,
additional patients will be enrolled and be treated at RP2D to evaluate the safety,
tolerability and efficacy.